INTERFERON COUNTERACTS PYRIMIDINONE-INDUCED HYPOREACTIVITY AND THE COMBINED TREATMENT HAS ANTITUMOR EFFECT IN MICE

  • 1 January 1984
    • journal article
    • research article
    • Vol. 75  (7) , 631-640
Abstract
A potent interferon (IFN) inducer, 2-amino-5-bromo-6-phenyl-4-pyrimidinone (ABPP), induced hyporeactivity in mice, and so IFN induced by subsequently administered ABPP was reduced even 120 h after the 1st administration of ABPP. This hyporeactivity was counteracted by the injection of IFN (10,000 IU or more) 3 h before the subsequent administrations of ABPP. Since the injection of > 5000 IU/mouse of IFN 3 h before an administration of ABPP enhanced the circulating IFN titer, the priming effect in vivo by IFN may result in the reduction of hyporeactivity. Administration of ABPP (200 mg/kg or 500 mg/kg) at intervals of 2 days and the injection of IFN (25,000 IU/mouse) 3 h before each administration of ABPP to neuroblastoma-bearing A/J mice reduced the mortality and completely cured 40% of the mice in each combined therapy group. The combined use of the IFN inducer with IFN may be available for patients with neoplasm or viral infection.